Status: Recruiting
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Participants needed: 130
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Opna Bio LLCUpdated: May 19, 2026Locations: 12
Eligibility criteria
Confirmed diagnosis of multiple myeloma (MM) [+2]
Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, W... [+12]